Treatments targeting γδ T cells and their cytokines could be good therapeutic targets for mitigating ischemic brain damage, given the truth that either genetic disruption or pharmacological blockade of γδ T cells, IL-17a or IL-21 shows a significant neuroprotective effect on ischemic brain damage in murine stroke (Table 1). This evidence concerns the gene IL21 and Stroke.